Skip to content

    Pfizer

    PFIZERNeutral
    Healthcare·7 Nov 2016
    Management Summary

    Pfizer India delivered a resilient quarter despite significant regulatory headwinds, including unanticipated price controls under Para 18 which impacted margins. The company is actively rationalizing its portfolio, evidenced by the ₹110 crore divestment of tail brands to Piramal. Management is transitioning to a new customer-centric 'route-to-market' structure and preparing for a major SAP rollout in 2017.

    Highlights

    8

    • Revenue of ₹552 crores, representing a 5% YoY growth

    • Regulatory pricing impacts (NLEM, WPI, Para 18) reduced revenue by ₹22 crores (4% impact)

    • Exceptional gain of ₹103 crores recorded from the sale of four brands to Piramal Enterprises

    • Profit from operations stood at ₹75 crores, down from ₹102 crores in Q1 FY17

    • Top 11 brands, contributing 69% of total revenue, grew by 8% YoY

    • Cash balance reached approximately ₹1400 crores, representing ~20% of market cap

    • Gross margin declined by ~500 bps YoY, primarily due to pricing impacts (2%) and inventory write-offs

    • Launched global patented product XELJANZ, clocking ₹1 crore in its debut quarter

    Concerns

    1

    • Regulatory Pricing Pressure (NLEM, WPI, Para 18)

    What Changed2

    vs Q3 FY17

    Tone shiftMixed → NeutralGuidance items3 → 4 (+1)

    Key financials

    Single quarter

    05 metrics
    1. 01Revenue₹552 Cr+5%YoY
    2. 02Profit from Operations₹75 Cr-26.5%QoQ
    3. 03Exceptional Item Gain₹103 Cr
    4. 04Cash Balance₹1,400 Cr
    5. 05Inventory Write-off₹5 Cr

    Segment breakdown

    Top 11 Brands
    69% Revenue Contribution8% Revenue Growth
    Hospital Segment
    15.5% Revenue Growth
    List

    Guidance & targets

    4
    CategoryTargetPriority
    Margin
    EBITDA Margin
    22-23%
    		Medium
    Revenue
    Corex Dx Annual Revenue
    ₹45-50 crores
    		High
    Other
    Divestment Revenue Adjustment
    -₹6 crores
    		High
    Other
    SAP Go-live Timeline
    July 2017
    		High

    Risks & concerns

    4
    RiskSeverity

    Regulatory Pricing Pressure (NLEM, WPI, Para 18)

    Impacted revenue by 4% (₹22 Cr) and is expected to persist as a quarterly headwind. — Both acknowledged

    high

    Fixed Dose Combination (FDC) Litigation

    Corex sales remain uncertain pending a Supreme Court hearing; growth is currently flat. — Both acknowledged

    medium

    Inventory Write-offs

    A one-time ₹5 crore write-off impacted gross margins this quarter. — Management acknowledged

    low

    Areas of Evasion(1)

    • Specifics on the acquisition pipeline despite high cash balances.

    Q&A highlights

    3

    “In terms of volume and price, if I take the 5% growth this quarter, 4% is volume-driven and 1% is price-driven.”

    Confirms that core demand remains healthy (4% volume growth) despite heavy regulatory pricing pressure.

    asked by Cindrella Carvalho, Dolat Capital

    2 min read5 chapters

    Detailed Narrative

    01

    Regulatory Pricing Headwinds

    Pfizer faced a significant ₹22 crore revenue hit this quarter due to a combination of NLEM, WPI, and Para 18 pricing mandates. This regulatory pressure accounted for a 4% drag on total revenue growth, which would have otherwise been 9%. Management expects this 4% impact to continue quarterly assuming the current portfolio mix remains stable.

    02

    Strategic Portfolio Rationalization

    The company concluded the sale of four legacy brands (Neko, Ferradol, Sloan’s, and Waterbury) to Piramal Enterprises for ₹110 crores. This divestment resulted in a ₹103 crore exceptional gain📎. Management noted that these brands were better suited for a pure OTC route, which Pfizer does not focus on, and investors should adjust for a ₹6 crore quarterly revenue reduction going forward⏳.

    03

    Corex and FDC Litigation Uncertainty

    Corex performance was flat YoY as the company awaits a Supreme Court hearing regarding Fixed Dose Combination (FDC) petitions. While sales have improved slightly compared to the immediate aftermath of the ban, they remain below historical levels. To mitigate this, Pfizer is scaling Corex Dx, which is expected to reach ₹45-50 crores in annual revenue.

    04

    Operational Restructuring and SAP Rollout

    Pfizer is restructuring its commercial teams into three specialized units: Critical Care (hospitals), Specialty Care (niche specialists), and Primary Care (mass brands). Simultaneously, the company has kicked off an SAP rollout planned for July 2017 to align with GST implementation. This project involves a ₹5 crore CAPEX and an ongoing ₹2.5 crore annual depreciation charge.

    05

    New Product Traction

    The launch of XELJANZ, a global patented Rheumatoid Arthritis product, is a key highlight of Pfizer's specialty strategy. The product generated ₹1 crore in its first quarter. Management emphasized that while global products take time to clear local regulatory hurdles (typically ~1 year), they are committed to fast-tracking launches where a strong portfolio fit exists.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.